Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

Recruiting now · Phase 1/Phase 2

Conditions studied: Neovascular (Wet) Age-Related Macular Degeneration

In brief

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

Key facts

Study ID
NCT07587515
Run by
Eyconis INC.
People needed
30
Starts
2026-05-19
Expected to finish
2028-05-01
Last updated by the study team
2026-07-07

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.